[HTML][HTML] Mortality in SARS-CoV-2 hospitalized patients treated with Remdesivir: a nationwide, registry-based study in Italy
P Russo, E Tacconelli, PP Olimpieri, S Celant… - Viruses, 2022 - mdpi.com
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …
recommending its use for the treatment of moderate-to-severe disease is still controversial …
[HTML][HTML] Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study
F Pieralli, F Pomero, F Dentali, C Norbiato… - BMC Infectious …, 2023 - Springer
Background Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of
this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 …
this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 …
[PDF][PDF] Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational …
E Mozaffari, A Chandak, Z Zhang, S Liang… - Clin Infect …, 2021 - scholar.archive.org
Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-
hospital all-cause mortality in a lar Page 1 © The Author(s) 2021. Published by Oxford University …
hospital all-cause mortality in a lar Page 1 © The Author(s) 2021. Published by Oxford University …
Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case–control study
A De Vito, M Poliseno, A Colpani, B Zauli… - Current Medical …, 2022 - Taylor & Francis
Introduction Since the start of the SARS-CoV-2 pandemic, several treatment options have
been proposed (eg steroids, heparin, antivirals and monoclonal antibodies). Remdesivir …
been proposed (eg steroids, heparin, antivirals and monoclonal antibodies). Remdesivir …
[HTML][HTML] Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis
N Veronese, F Di Gennaro, L Frallonardo… - Scientific Reports, 2024 - nature.com
Remdesivir (RDV) was the first Food and Drug Administration (FDA)-approved medication
for COVID-19, with discordant data on efficacy in reducing mortality risk and disease …
for COVID-19, with discordant data on efficacy in reducing mortality risk and disease …
[HTML][HTML] Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients: A propensity score matched analysis
M Karolyi, L Kaltenegger, E Pawelka, A Kuran… - Wiener klinische …, 2022 - Springer
Background Remdesivir is the only antiviral agent approved for the treatment of hospitalized
coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen. Studies …
coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen. Studies …
[HTML][HTML] Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience
E Attena, A Caturano, A Annunziata… - European Journal of …, 2023 - Springer
Introduction Remdesivir exerts positive effects on clinical improvement, even though it
seems not to affect mortality among COVID-19 patients; moreover, it was associated with the …
seems not to affect mortality among COVID-19 patients; moreover, it was associated with the …
Real-world effectiveness of remdesivir in adults hospitalized with coronavirus disease 2019 (COVID-19): a retrospective, multicenter comparative effectiveness study
Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
[HTML][HTML] Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected …
L Pilgram, KS Appel, MM Ruethrich, CEM Koll… - Infection, 2023 - Springer
Objectives The use of remdesivir (RDV) as the first drug approved for coronavirus disease
2019 (COVID-19) remains controversial. Based on the Lean European Open Survey on …
2019 (COVID-19) remains controversial. Based on the Lean European Open Survey on …
Real-world effectiveness of remdesivir in adults hospitalized with Covid-19: a retrospective, multicenter comparative effectiveness study
Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of SARS-CoV-2. Methods This was a retrospective comparative …
remdesivir in the treatment of SARS-CoV-2. Methods This was a retrospective comparative …